Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm. Our purpose – and passion – is to seek out, enable and empower the most promising life science therapeutics innovations.

We help turn new science into new products, improving outcome for patients. And we help create value for innovators, investors and health care systems around the world.

Read more… 

Europe’s biotech ecosystem is broken at the ends

Europe's biotech ecosystem is broken at the ends The middle holds. The ends are collapsing. Fresh startups and near-commercial firms are strained and cannot access capital in EU. Without more qualified early-stage funding now, there will be no mature EU biotech to...

Biotech innovation is slowing down! — are we entering a new opportunity window?

In late 2025, Sunstone set out to understand a simple question: how has the Novo Nordisk Foundation's ~€500M investment into BioInnovation Institute (BII) Institute (2018) influenced the creation of new biotech companies in Denmark? The answer surprised us. After...

MinvervaX CFO & CDO Appointment

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief...

Is biotech venture capital investing more to return less?

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...

An update on M&A returns for biotech venture capital

Back in in 2019 Sunstone started sharing studies of European venture capital funded successes – i.e. M&A transactions. In 2021 we started adding US M&A’s to the data and later the same year we evaluated to which extent an IPO impacted the observations made....

Investment Strategy

Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans.  

Read more…

Funds

Our portfolio is managed through a series of funds. Fund IV, focusing solely on therapeutics, is actively pursuing new investment opportunities.

Read more…

People

As a team, we represent a broad range of highly relevant education, experience and competencies. Come on in and meet the team.

Read more…

Portfolio

An overview of the companies in our portfolio – currently active, completed M&As and completed IPOs.

Read more…

News

Newest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.

Read more…

Contact

Find our visiting address, contact info and some guidance and a contact form for submitting projects for evaluation.

Read more…

New science becomes new products

Since the inception of Sunstone in 2007, we have contributed in bringing several new drugs into the market and have supported a large number of clinical trials:

New drugs approved

Pre-clinical drug candidates

Clinical phase 1 studies

Clinical phase 2 studies

Clinical phase 3 studies

Sunstone Life Science Ventures is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing